## Abstract ## BACKGROUND. The objective of the current study was to examine whether emotional wellβbeing predicted survival in a large sample of patients with head and neck cancer who were participating in multicenter clinical trials. ## METHODS. Participants were enrolled in 2 Radiation Oncolo
Reply to Emotional Well-Being Does Not Predict Survival in Head and Neck Cancer Patients : A Radiation Therapy Oncology Group study
β Scribed by James C. Coyne; Thomas F. Pajak; Deborah Watkins Bruner
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 39 KB
- Volume
- 112
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
A Radiation Therapy Oncology Group Study I n their recent article, Coyne et al. 1 vastly overstated the quality of their study and the meaning of their findings.
Poor Measurement
They used only 4 items from an Emotional Well-Being subscale, which hardly constitutes a reliable assessment of depression or anything else, and produces little variance. Coyne et al stated that the subscale contains 5 items, 1 but it actually contains 6. 2 Furthermore, the questions utilized do not assess how the person handles their distress (eg, by avoidance, suppression of emotion, substance abuse, etc.). 3 Moreover, although the patients in the study had squamous cell carcinomas, the validation was performed on a sample of 240 breast cancer patients. Reliability and validity are population specific.
π SIMILAR VOLUMES
A Radiation Therapy Oncology Group Study I n their recent article, Coyne et al. 1 vastly overstated the quality of their study and the meaning of their findings. ## Poor Measurement They used only 4 items from an Emotional Well-Being subscale, which hardly constitutes a reliable assessment of dep
A group of 154 patients with locally advanced head and neck cancer, treated with platinum-based induction chemotherapy, were followed up for 5 years and several pretreatment characteristics were analyzed for possible correlation to a complete response (CR) to chemotherapy, time to progression (TTP)